Collagenase Injections for Pain Associated with Penile Curvature in Peyronie's Disease

Understanding Collagenase Treatment in Peyronie's Disease

The American Urological Association (AUA) guidelines clearly state that "intralesional collagenase is a therapy for curvature; it does not treat pain or erectile dysfunction" 1
CCH (Xiaflex) is FDA-approved specifically for the reduction of penile curvature in patients with stable Peyronie's disease with curvature between 30° and 90° who maintain intact erectile function 1, 2
CCH treatment requires a palpable plaque confirmed on physical examination and stable disease without active progression 2, 3

For patients experiencing pain in the active phase of Peyronie's disease, oral non-steroidal anti-inflammatory medications are the recommended treatment option 4, 3
Pain should be assessed using a visual analog scale and periodically reassessed to measure treatment efficacy 5, 4

The IMPRESS I and II trials, which established the FDA-approved protocol for CCH, focused on curvature reduction rather than pain relief 1
These definitive trials included patients with average PD symptom durations of 46.8-57.6 months, indicating stable rather than acute disease 1

The approved protocol involves up to eight injections of 10,000 U over 24 weeks, combined with clinician and patient modeling 1, 2
Patients should be counseled about potential adverse events, including penile ecchymosis, swelling, pain, and rare but serious complications like corporal rupture 1
In the IMPRESS trials, 84.2% of patients in the collagenase groups experienced at least one adverse event, with most being mild or moderate 1

For patients with active disease and pain, the AUA guidelines specifically recommend oral NSAIDs as the appropriate treatment 4, 3
Pain management should be periodically reassessed to measure treatment efficacy 5

CCH treatment should only be administered by clinicians experienced in urological disease treatment 2
The average improvement in curvature with CCH is modest (approximately 17° versus 9.3° with placebo), and patients should have realistic expectations 1, 2
Using CCH specifically for pain relief represents off-label use not supported by major guidelines and could delay appropriate pain management 1, 4
Patients should be informed that while curvature may improve with CCH, this is not a treatment specifically targeting pain relief 1, 2

The American Urological Association characterizes active disease by dynamic symptoms, penile pain, developing plaque, and progressive deformity, typically lasting 3-12 months 6
The American Urological Association defines stable disease as symptoms unchanged for at least three months, minimal or no pain, established plaque, and stable curvature 6

The European Association of Urology recommends pain management using NSAIDs as first-line therapy for penile pain during the active phase, with pain assessment using a visual analog scale and periodic reassessment 7, 8
The European Association of Urology suggests considering PDE5 inhibitors, such as tadalafil 5mg daily, to reduce collagen deposition and lower curvature progression rates 9

The American Urological Association recommends intralesional collagenase injections as the only FDA-approved non-surgical therapy for stable disease with curvature between 30° and 90° and intact erectile function 9
The American Urological Association suggests penile traction therapy for collagen remodeling, requiring extended daily use, and low-intensity extracorporeal shockwave therapy for pain relief, but not for curvature reduction 9
The American Urological Association recommends surgical options, such as tunical plication, plaque incision/excision with grafting, and penile prosthesis surgery, for stable disease, considering factors like erectile function and curvature severity 8

The European Association of Urology advises determining disease phase, assessing for erectile dysfunction, and documenting penile curvature and plaque characteristics for initial assessment 7, 6
For active disease, the European Association of Urology recommends NSAIDs for pain management and considering PDE5 inhibitors, while avoiding ineffective oral therapies 7, 8, 9
For stable disease, the American Urological Association suggests observation for mild curvature, intralesional collagenase injections for moderate curvature, and surgical options for severe curvature or failed conservative therapy, considering erectile function 8, 9